NASDAQ:COLL - Collegium Pharmaceutical Stock Price, Forecast & News

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

Collegium Pharmaceutical Inc (NASDAQ:COLL) issued its quarterly earnings data on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.03. The specialty pharmaceutical company earned $72.94 million during the quarter, compared to the consensus estimate of $74.32 million. Collegium Pharmaceutical had a negative return on equity of 13.14% and a negative net margin of 3.86%. The business's quarterly revenue was up 3.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. View Collegium Pharmaceutical's Earnings History.

Collegium Pharmaceutical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Collegium Pharmaceutical.

6 brokerages have issued 1 year price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $22.00 to $36.00. On average, they anticipate Collegium Pharmaceutical's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.

News coverage about COLL stock has been trending negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Collegium Pharmaceutical earned a news impact score of -2.3 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Collegium Pharmaceutical.

Collegium Pharmaceutical saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,040,000 shares, an increase of 22.9% from the December 15th total of 1,660,000 shares. Based on an average daily trading volume, of 444,800 shares, the short-interest ratio is currently 4.6 days. Currently, 7.0% of the shares of the company are short sold. View Collegium Pharmaceutical's Current Options Chain.

Some companies that are related to Collegium Pharmaceutical include Axsome Therapeutics (AXSM), Zai Lab (ZLAB), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Uniqure (QURE), Genmab A/S (GMAB), Biohaven Pharmaceutical (BHVN), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), Karuna Therapeutics (KRTX), ChemoCentryx (CCXI), Epizyme (EPZM), Zogenix (ZGNX), ArQule (ARQL) and Arena Pharmaceuticals (ARNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include GALAPAGOS NV/S (GLPG), AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Celgene (CELG), Bausch Health Companies (BHC), Canopy Growth (CGC), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT) and Ocular Therapeutix (OCUL).

(COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of COLL stock can currently be purchased for approximately $21.85.

Collegium Pharmaceutical has a market capitalization of $732.63 million and generates $280.41 million in revenue each year. The specialty pharmaceutical company earns $-39,130,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Collegium Pharmaceutical employs 266 workers across the globe.View Additional Information About Collegium Pharmaceutical.

The official website for Collegium Pharmaceutical is http://www.collegiumpharma.com/.

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.